Table
1: Clinical characteristics
of the patients.
|
Average
of study group 12.3 ± 3.1 years (range : 4.7-18) |
|
|
Number
and gender of patients 132 patients ( 49 male, 83 female) |
|
|
Echocardiographic
findings Normal |
(n:
132) 90 (68.2%) |
|
Mitral valve prolapsus |
23 (17.4%) |
|
Atrial septal defect |
6 (4.5%) |
|
Transposition of great arteries |
1 (0.8%) |
|
Mitral valve insuffiency |
9 (6.8%) |
|
Aort valve insuffiency |
2 (1.5%) |
|
Dilate cardiomyopathy |
1 (0.8%) |
|
24
hour Rhythm Holter monitoring Normal |
(n:
99) 70 (53.3%) |
|
WPW |
14 (10.6%) |
|
SVES |
8(6.1%) |
|
VES |
5 (3.8%) |
|
VT |
1(0.8%) |
|
Medication
No medication |
83
(62.9%) |
|
B-
Blockers |
43
(32.6%) |
|
Others (ACEI, Digoxin.. etc) |
6
(4.5%) |
|
Indıcation
for TEEPs Evaluation of symptoms |
|
|
Palpitation |
61
(46.2%) |
|
Palpitation,chest
pain |
22
(16.7%) |
|
Palpitation,
syncope |
8
(6.1%) |
|
Risk assessment of WPW |
18
(13.6%) |
|
Evaluation of tachycardia mechanism |
23
(17.4) |
WPW: Wolf
Parkinson White, SVES: Supra-Ventricular Extrasystole, VES: Ventricular Extrasystole,
VT: Ventricular Tachycardia, ACEI: Angiotensin Converting Enzyme Inhibitors.